“RDA: better chemotherapy management”
description
Transcript of “RDA: better chemotherapy management”
© 2013 RNA Diagnostics Inc. All rights reserved. Confidential 1
“RDA: better chemotherapy management”
Investor PresentationApril 2013
© 2013 RNA Diagnostics Inc. All rights reserved. Confidential 2
Would you prefer to know if your
chemotherapy is working or not NOW
Would you like to endure 26 weeks of chemotherapy
side effects?OR
© 2013 RNA Diagnostics Inc. All rights reserved. Confidential 3
Problem: Adverse Side Effects 50% of breast cancer patients
receive chemotherapy 75% of chemo patients derive no
long term benefit All patients suffer adverse side
effects
© 2013 RNA Diagnostics Inc. All rights reserved. Confidential 4
Solution:RDA™ improved chemotherapy management
First “Real Time” chemotherapy guidance tool Only prognostic test to measure response to
chemotherapy early in treatment Discovered in clinical trial (NCIC MA.22) Protected by broad patents
© 2013 RNA Diagnostics Inc. All rights reserved. Confidential 5
Benefits for Patients, Physicians and Payers
For non responding patients, treatment can be altered quicklySignificant reduction in adverse effectsSwitch to alternate treatment improves survival benefit
Objective & useful tool for physiciansCost savings for healthcare payers ($20k - $60K / patient)
Maureen E. Trudeau MD, FRCPCHead, Division of Medical Oncology/Hematology, Sunnybrook Health Sciences Centre, Head, Systemic Therapy Program, Odette Cancer Centre, Toronto, Canada
“RDA holds the prospect of providing oncologists with an extremely valuable method for managing the chemotherapy of their breast cancer patients”
© 2013 RNA Diagnostics Inc. All rights reserved. Confidential 6
Technology : RNA Disruption Assay (RDA™)
National Cancer Institute of Canada breast cancer trial (MA.22)
Clear discrimination between responders and non-responders
RDA strongly correlates with pathological complete response (pCR) at end of therapy
Negative Predictive Value = 0.99
False Negative 1%
RDA™ Performance Characteristics
© 2013 RNA Diagnostics Inc. All rights reserved. Confidential 7
RDA™ Clinical ScoringRDA Score Clinical Guidance
1 Patient is a non-responder, chemotherapy is not working. Consider alternate approach
NPV 0.99 False Negative Rate of 0.01
2 Patient is a partial responder – chemotherapy should be continued
3 High level of RNA structural dysfunction – chemotherapy is working. Patient 3x more likely to achieve pCR than untested cohort
PPV 0.17
© 2013 RNA Diagnostics Inc. All rights reserved. Confidential 8
RDA: Clinical SystemChemotherapy selected Chemotherapy infusion Breast tumour biopsy
Fine Needle Aspirate,2 samples
Tumour RNA FixativeRNA Disruption analysed at Rna DIAGNOSTICS central lab
Raw data analysed by Rna DIAGNOSTICS using proprietary algorithms. Results transmitted to clinician
© 2013 RNA Diagnostics Inc. All rights reserved. Confidential 9
Management TeamManagement CEO: Dr. Ken Pritzker, MD, FRCPC
Former Chief Pathology & Lab Medicine, Mount Sinai Hospital, Toronto, Cancer diagnostics expert CSO: Dr. Amadeo Parissenti, PhD
Cancer Research Scientist, Laurentian University VP Corporate Development: John Connolly, MBA
Former partner at MDS Capital Corp. – 15 year Medtech entrepreneur CFO: John Jordan, MBA, CMA, CPA, ABV
Financial executive, experienced working with high growth technology companies
Clinical Advisory Board Maureen Trudeau, MA, MD, FRCPC - Head , Medical Oncology, Sunnybrook
Health Sciences, Toronto, Canada Michael Untch, MD, PhD– Head , German Breast Group, Berlin, Germany Gunter von Minckwitz, MD, PhD – Chairman, German Breast Group, Frankfurt,
Germany Harry Bear, MD, PhD – Principal Investigator, NSABP, Virginia Commonwealth
University, USA
© 2013 RNA Diagnostics Inc. All rights reserved. Confidential 10
Market Opportunity in Breast Cancer
Japan & Australia
USA & Canada
Europe
Total Developed World
BRIC
Total
59,236
205,446
425,147
726,199
379,738
1,105,937
Developed World & BRIC Countries Breast Cancer
New Case Incidence 2008(Source: WHO GLOBOCAN 2008)
Size of Breast Cancer Market
$525M# of Patients per year in the developed world
350,000Sales Forecast
by 2018
$100 M
Total Addressable Market
© 2013 RNA Diagnostics Inc. All rights reserved. Confidential 11
Competition :Oncologists need better tools
Physical Exam
Physical Exams do not predict efficacy
Imaging Over estimates efficacy
Too late to impact clinical decision making
Gene panels predict probability of 10 year recurrence
Don’t predict efficacy
© 2013 RNA Diagnostics Inc. All rights reserved. Confidential 12
Sales Forecast
© 2013 RNA Diagnostics Inc. All rights reserved. Confidential 13
Rna Diagnostics Inc.
Unique solution for serious cancer problem Large market - $500M in Breast Cancer Strong IP and clinical data Clinical trials underway Rapid route to market
© 2013 RNA Diagnostics Inc. All rights reserved. Confidential 14
“RDA: better chemotherapy management”
Investor PresentationApril 2013